Skip to main content
Figure 1 | Orphanet Journal of Rare Diseases

Figure 1

From: Lack of synergistic effect of resveratrol and sigma-1 receptor agonist (PRE-084) in SOD1G93A ALS mice: overlapping effects or limited therapeutic opportunity?

Figure 1

PRE + RSV administration improves locomotor performance and delays disease onset in SOD1G93Amice. (A) Rotarod test showed significant improvement in PRE + RSV treated animals compared to untreated littermates. Female but not male SOD1G93A mice treated with PRE + RSV had better performance at advanced stages than RSV and PRE-084 alone treated mice. Values are expressed as mean ± SEM. **p < 0.01, ***p < 0.001 vs. untreated; #p < 0.05 vs. PRE-084 and @p < 0.05 vs. RSV treated SOD1G93A mice. (B) Clinical onset analysis (Mantel-Cox test) revealed that PRE + RSV combination significantly delayed by 2 weeks the signs of disease onset both in female and male SOD1G93A mice.

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172